Omeros Corporation (OMER) News
Filter OMER News Items
OMER News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest OMER News From Around the Web
Below are the latest news stories about OMEROS CORP that investors may wish to consider to help them evaluate OMER as an investment opportunity.
7 Short-Squeeze Stocks That Are Screaming for SpeculationWhile the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. |
Omeros Corporation (NASDAQ:OMER) Q3 2023 Earnings Call TranscriptOmeros Corporation (NASDAQ:OMER) Q3 2023 Earnings Call Transcript November 10, 2023 Operator: Good afternoon, and welcome to today’s earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode. After the company’s remarks, we will conduct a question-and-answer session. And please be advised that this call is being recorded at the […] |
Q3 2023 Omeros Corp Earnings CallQ3 2023 Omeros Corp Earnings Call |
Omeros Corporation Reports Third Quarter 2023 Financial ResultsSEATTLE, November 09, 2023--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2023, which in |
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023SEATTLE, November 06, 2023--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2023, on Thursday, November 9, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. |
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic MicroangiopathySEATTLE, November 03, 2023--Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), 14 of whom had "high-risk" TA-TMA. Narsoplimab is Omeros’ investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system. The report was authored by an external group of investigators |
Omeros Corporation Announces Upcoming Presentations at ASH Annual MeetingSEATTLE, November 02, 2023--Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to OMS906, Omeros’ investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 65th Annual Meeting of the American Society of Hematology (ASH), to be held December 9-12, 2023 in San Diego. |
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical OfficerSEATTLE, October 19, 2023--Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros’ chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics. A highly tenured physician, scientist and pharmaceutical leader, Dr. Grauer brings to Omeros over 20 years of industry experience across a broad range o |
UPDATE 1-Omeros to terminate kidney disease trial as therapy fails late-stage studyOmeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the main goal of the late-stage study. An interim analysis showed the drug failed to demonstrate a statistically significant improvement in reducing elevated levels of protein in urine compared to placebo. The company was studying narsoplimab for the treatment of immunoglobulin A (IgA) nephropathy, in which germ-fighting protein builds up in the kidneys. |
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA NephropathySEATTLE, October 16, 2023--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today provided an update regarding the interim analysis outcome in ARTEMIS-IGAN, the Company’s Phase 3 trial evaluating narsoplimab for t |